APA (7th ed.) Citation

AL, W., K, Z., M, H., CF, E., CC, B., JL, K., . . . A, A. (2023). Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: An open-label, non-inferiority, randomised, controlled trial. The Lancet. Infectious diseases, 23(9), 1062. https://doi.org/10.1016/S1473-3099(23)00139-1

Chicago Style (17th ed.) Citation

AL, Wilkinson, et al. "Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 Administered Concomitantly with Bivalent Oral Poliovirus Vaccine: An Open-label, Non-inferiority, Randomised, Controlled Trial." The Lancet. Infectious Diseases 23, no. 9 (2023): 1062. https://doi.org/10.1016/S1473-3099(23)00139-1.

MLA (9th ed.) Citation

AL, Wilkinson, et al. "Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 Administered Concomitantly with Bivalent Oral Poliovirus Vaccine: An Open-label, Non-inferiority, Randomised, Controlled Trial." The Lancet. Infectious Diseases, vol. 23, no. 9, 2023, p. 1062, https://doi.org/10.1016/S1473-3099(23)00139-1.